High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods.
RET fusions; RET point mutations
External quality assessment schemes
Medullary thyroid carcinomas
Non-small cell lung cancer
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
26
01
2024
accepted:
03
08
2024
revised:
29
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
aheadofprint
Résumé
This study describes the external quality assessment (EQA) scheme for molecular testing of RET alterations in non-small cell lung cancer (NSCLC), medullary thyroid carcinomas (MTC), and non-MTC. The lead panel institute and Quality Assurance Initiative in Pathology (Qualitätssicherungs-Initiative Pathologie [QuIP] GmbH) selected formalin-fixed paraffin-embedded (FFPE) tissue from MTC for RET mutation testing by next-generation sequencing (NGS) methods and FFPE tissue from NSCLC and non-MTC for RET gene fusion testing using either in situ hybridisation (ISH) or NGS methods, forming 3 sub-schemes of the EQA scheme. Tissue material underwent an internal validation phase followed by an external testing phase. The internal validation phase served as a cross-validation step conducted by panel institutes. In the external testing phase, the number of participating institutes in the RET point mutation sub-scheme, RET fusion (ISH) sub-scheme, and RET fusion (NGS) sub-scheme was 32, 24, and 38, respectively. The reported success rates for external testing were 96.0%, 89.5%, and 93.5% for the RET point mutation, the ISH RET fusion, and the NGS RET fusion EQA sub-schemes, respectively. These findings confirm the reliability of the NGS method in detecting RET alterations and align with current screening recommendations. Overall, 31 institutes were certified for RET point mutation testing by NGS methods, 22 institutes were certified for RET fusion testing by ISH, and 36 institutes were certified for RET fusion testing by NGS methods. Results can be employed to inform real-world diagnostic decisions in Germany, Austria, and Switzerland.
Identifiants
pubmed: 39120655
doi: 10.1007/s00428-024-03890-w
pii: 10.1007/s00428-024-03890-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Subbiah V, Cote GJ (2020) Advances in targeting RET-dependent cancers. Cancer Discov 10(4):498–505. https://doi.org/10.1158/2159-8290.CD-19-1116
doi: 10.1158/2159-8290.CD-19-1116
pubmed: 32094155
pmcid: 7125013
Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F (2020) State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol 38(11):1209–1221. https://doi.org/10.1200/JCO.19.02551
doi: 10.1200/JCO.19.02551
pubmed: 32083997
pmcid: 7145587
Salvatore D, Santoro M, Schlumberger M (2021) The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17(5):296–306. https://doi.org/10.1038/s41574-021-00470-9
doi: 10.1038/s41574-021-00470-9
pubmed: 33603219
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simoes M, Tallini G, Mete O (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33(1):27–63. https://doi.org/10.1007/s12022-022-09707-3
doi: 10.1007/s12022-022-09707-3
pubmed: 35288841
Guilmette J, Nose V (2018) Hereditary and familial thyroid tumours. Histopathology 72(1):70–81. https://doi.org/10.1111/his.13373
doi: 10.1111/his.13373
pubmed: 29239041
Drilon A, Hu ZI, Lai GGY, Tan DSW (2018) Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15(3):151–167. https://doi.org/10.1038/nrclinonc.2017.175
doi: 10.1038/nrclinonc.2017.175
pubmed: 29134959
FDA (2022) RETEVMO® (selpercatinib) capsules, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf Accessed 2023
EMA (2023) Retsevmo. https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo Accessed 2023
Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M, Drilon A, Scarpa A, Andre F, Douillard JY, Curigliano G (2021) ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 32(3):337–350. https://doi.org/10.1016/j.annonc.2020.11.021
doi: 10.1016/j.annonc.2020.11.021
pubmed: 33455880
Dufraing K, Fenizia F, Torlakovic E, Wolstenholme N, Deans ZC, Rouleau E, Vyberg M, Parry S, Schuuring E, Dequeker EMC, ABSL IQ (2021) Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. Virchows Arch 478(3):553–565. https://doi.org/10.1007/s00428-020-02928-z
doi: 10.1007/s00428-020-02928-z
pubmed: 33047156
Lazure P, Sireci A, Subbiah V, Murray S, Grohe C, Sherman SI, Kelly E, Bubach P, Peloquin S (2023) Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Med Educ 23(1):410. https://doi.org/10.1186/s12909-023-04396-w
doi: 10.1186/s12909-023-04396-w
pubmed: 37277734
pmcid: 10241144
Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Kempny G, Kazmierczak M, Flechtenmacher C, Baretton G, Weichert W, Horst D, Klauschen F, Gassner UM, Bruggemann M, Vogeser M, Schirmacher P, Stenzinger A (2023) Structure and content of the EU-IVDR: current status and implications for pathology. Pathologie, Heidelb, p 1–13. https://doi.org/10.1007/s00292-022-01176-z
Spitzenberger F, Patel J, Gebuhr I, Kruttwig K, Safi A, Meisel C (2022) Laboratory-developed tests: design of a regulatory strategy in compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]). Ther Innov Regul Sci 56(1):47–64. https://doi.org/10.1007/s43441-021-00323-7
doi: 10.1007/s43441-021-00323-7
pubmed: 34291407
Liu Y, Wu S, Zhou L, Guo Y, Zeng X (2021) Pitfalls in RET fusion detection using break-apart FISH probes in papillary thyroid carcinoma. J Clin Endocrinol Metab 106(4):1129–1138. https://doi.org/10.1210/clinem/dgaa913
doi: 10.1210/clinem/dgaa913
pubmed: 33382428
Radonic T, Geurts-Giele WRR, Samsom KG, Roemen G, von der Thusen JH, Thunnissen E, Meijssen IC, Sleddens H, Dinjens WNM, Boelens MC, Weijers K, Speel EJM, Finn SP, O’Brien C, van Wezel T, Cohen D, Monkhorst K, Roepman P, Dubbink HJ (2021) RET fluorescence in situ hybridization analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer. J Thorac Oncol 16(5):798–806. https://doi.org/10.1016/j.jtho.2021.01.1619
doi: 10.1016/j.jtho.2021.01.1619
pubmed: 33588111